Olaparib Prolongs rPFS in Metastatic Castration-Resistant Prostate Cancer
By blinded independent review, there was a 39% reduction in the risk of progression or death with olaparib.
Diagnosis & Disease Information
Can ARDT Protect Against Poor Outcomes of COVID-19?
Most outcomes were numerically, but not significantly, better in patients who received ARDT.
PHS290 May Help Predict Lifetime Risk of Metastatic or Fatal Prostate Cancer
Men of African ancestry had the highest risk of developing metastatic prostate cancer when compared with men of other ancestries.
First Predictive Biomarker for ADT Use in Prostate Cancer Validated
Investigators developed a multimodal deep learning architecture to learn from both clinicopathologic and digital imaging histopathology data and identify different outcomes by treatment type.
AI Tool More Accurately Predicts Long-Term Outcomes in Prostate Cancer
An AI tool outperformed NCCN guidelines for predicting biochemical failure, distant metastasis, prostate cancer-specific survival, and overall survival.
Same-Day Robot-Assisted Prostate Cancer Surgery Safe, Feasible
Patients who underwent robot-assisted radical prostatectomy and were discharged the same day had complication and 90-day readmission rates similar to those who had the procedure as inpatients.
LND Extent During Prostate Cancer Surgery Not Linked to Survival
A study of men with prostate cancer found no association between extent of lymph node dissection during radical prostatectomy and survival outcomes.
Nonmetastatic CRPC Prevalence, Natural History Explored
The natural history of nonmetastatic castration-resistant prostate cancer (nmCRPC) can serve as a benchmark for advances in imaging and treatment, according to investigators.
- Loading...
Loading...
Next post in ASCO GU 2022
Loading... 
Loading...